Cogent Biosciences Inc (COGT NASDAQ) stock market data APIs
$7.5501
-0.08(-1.1%)
as of July 3, 2025
Try our APIs with
free plan!
Cogent Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Prev. Close
7.5501
Open
7.4708
High
7.691
Low
7.2243
52 wk Range
3.72-12.61
Market Cap
844 M
Shares Outstanding
114 M
EPS
-0.5249
Beta
0.226
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cogent Biosciences Inc data using free add-ons & libraries
Get Cogent Biosciences Inc Fundamental Data
Cogent Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -285 976 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.5771
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cogent Biosciences Inc News
New
Citi maintains buy rating on Cogent stock ahead of trial results
Investing.com - Citi maintained its buy rating and $15.00 price target on Cogent (NASDAQ:COGT) stock, opening a 30-day Upside Catalyst Watch ahead of upcoming clinical trial results. According to Inve...
Piper Sandler maintains Cogent stock rating ahead of pivotal trial data
Piper Sandler reiterated its Overweight rating and $24.00 price target on Cogent Biosciences (NASDAQ:COGT) Monday as the company approaches a crucial data readout for its drug bezuclastinib. Currently...
Cogent Secures Up To $400 Mln Debt Facility From SLR Capital For Growth Strategy
(RTTNews) - On Wednesday, Cogent Biosciences, Inc. (COGT), a biotechnology company, announced it has secured a debt financing facility of up to $400 million from credit funds managed by SLR Capital Pa...
Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against other best low...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
